hGLP1R(SD) Rat

The glucagon-like peptide-1 receptor (GLP-1R), encoded by the GLP1R gene, is the receptor for endogenous glucagon-like peptide-1 (GLP-1) and belongs to the class B (secretin-like) G protein-coupled receptor (GPCR) family. GLP-1R contains a characteristic seven-transmembrane domain (7TM) and a relatively large N-terminal extracellular domain, and mediates downstream signaling upon binding to GLP-1 ^[1]. GLP-1R is predominantly expressed in pancreatic β cells and is also detected in the central nervous system and other tissues. Upon ligand activation, GLP-1R can undergo internalization and participate in the regulation of insulin secretion and energy metabolism ^[2-3]. Activation of GLP-1R enhances glucose-dependent insulin secretion and inhibits glucagon secretion, while also delaying gastric emptying and reducing food intake ^[3-4]. GLP-1 receptor agonists (GLP-1RAs) are important therapeutic agents for the treatment of type 2 diabetes (T2D) and obesity, and improve glycemic control and promote weight loss through these multiple mechanisms ^[4]. In addition, GLP-1R-related signaling has been extensively investigated for its potential neuroprotective effects. Neuroprotective effects of GLP-1R agonists have been observed in animal models of stroke, although their clinical value for the direct treatment of acute stroke requires further investigation ^[5].

The hGLP1R(SD) Rat was generated by gene editing to replace a partial coding sequence of exon 1 and a partial sequence of intron 1 of the rat Glp1r gene with "Exon 1~2 of Human GLP1R CDS (without signal peptide)-Human GLP1R intron 2-Exon 3~13 of Human GLP1R CDS-hGH pA", while retaining the genomic sequence encoding the signal peptide of rat GLP1R. Its potential applications mainly include mechanistic studies of type 2 diabetes (T2D), obesity, and other metabolic diseases, as well as pharmacological studies of GLP-1R-targeted therapeutics, candidate drug screening, and evaluation of their potential effects.